By Eric D. Peterson, MD, MPH, FAHA, Committee on Scientific Sessions Program Chair
After three days of walking around Scientific Sessions, your feet could probably use a break. So, take advantage of “Wear Sneakers Day” to enjoy a little extra comfort while showing your support of regular exercise.
Today’s scientific program includes two Late Breaking Science sessions, beginning with “New Insights into the Risks, Benefits and Costs of Antithrombotic Therapy” at 10:45 a.m. The session will feature the latest results from the recent COMPASS, RE-DUAL PCI, POISE-2 PCI, GEMINI-ACS-1 and PRAGUE-18 trials. During the day’s second Late Breaking session, “Evaluating Quality Improvement and Patient Centered Care Interventions,” which begins at 3:45 p.m., investigators will present results from the SWEDEHEART, STIC2IT, ACS QUIK, ICARE-ACS, DECIDE-LVAD and STEMI ACCELERATOR-2 trials.
There are also two Frontiers in Science summits today. Beginning at 9 a.m. in rooms 154-158, ACC North, the Stem Cells Summit includes a full day of sessions featuring rapid-fire presentations by leading stem cell researchers. The Vascular Disease Summit, which begins at 3:45 p.m. in room 210D, Main Building, will feature presentations from investigators engaged in cutting-edge research and PVD “frontier science.”
Recognizing the growing emphasis on individualized care, today’s program also includes a special Precision Medicine Summit with sessions focusing on big data initiatives, “omics” research and technologies, and improving diagnostic precision in cardiomyopathies and heart failure. The Precision Medicine Summit begins at 9 a.m. in Hall D.
For information on AHA’s Institute for Precision Cardiovascular Medicine, be sure to stop by the Recharge Institute Lounge for demos of the AHA Precision Medicine Platform and My Research Legacy, as well as opportunities for one-on-one discussions with precision medicine experts, including Institute staff and leadership.
Today’s program also includes a special global health symposium celebrating the 50th anniversary of Fogarty International Center at National Institutes of Health. With three consecutive sessions beginning at 2 p.m. in Ballroom A, 3rd Level, Main Building, the symposium will showcase the broad reach of Fogarty-supported research and training.
And don’t forget, today is your last chance to visit the exhibits in the Science and Technology Hall to learn about the latest drugs, devices, tools and technologies related to cardiac care. Check the Final Program and the Mobile Meeting Guide for the most up-to-date information on today’s educational programming, networking opportunities and special events.
Late-Breaking Science V: New Insights into the Risks, Benefits and Costs of Antithrombotic Therapy
LBS.05 | 10:45 a.m.-Noon Tuesday | Main Event I, Hall D, Main Building
|COMPASS — Costs Impact Rivaroxaban Plus Aspirin Versus Aspirin in the COMPASS Trial||COMPASS evaluated whether rivaroxaban 5 mg twice-daily, or rivaroxaban 2.5 mg twice-daily in combination with aspirin 100 mg daily, is superior to aspirin 100 mg daily for prevention of myocardial infarction, stroke or CV death in patients with stable CAD or peripheral vascular disease.|
|RE-DUAL PCI — Subgroup Analysis from the RE-DUAL PCI Trial: Dual Antithrombotic Therapy with Dabigatran in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention||The RE-DUAL PCI trial evaluated the safety and efficacy of a dual antithrombotic therapy regimen using dabigatran and a P2Y12 platelet antagonist, and compared this with a “triple therapy” with warfarin, aspirin and a P2Y12 platelet antagonist.|
|POISE-2 PCI Substudy — Aspirin in Patients with Previous Percutaneous Coronary Intervention (PCI) Undergoing Noncardiac Surgery||This substudy of POISE-2 was designed to evaluate the effect of aspirin in patients with previous PCI undergoing noncardiac surgery.|
|GEMINI-ACS-1 — P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes||This trial had an embedded feature of mandatory reporting of CYP2C19 metabolizer status for patients treated with clopidogrel or ticagrelor, with tracking of how these results influenced subsequent P2Y12 inhibitor choices.|
|PRAGUE-18 — One-Year Outcomes of Patients with Acute Myocardial Infarction Treated with Primary Angioplasty and Randomized to Prasugrel versus Ticagrelor||This long-term follow-up focused on a comparison of prasugrel and ticagrelor, including the safety of post-discharge, economically motivated switch from the study drugs to clopidogrel.|
Late-Breaking Science VI: Evaluating Quality Improvement and Patient Centered Care Interventions
LBS.06 | 3:45-5:15 p.m. Tuesday | Ballroom CD, 3rd Level, Main Building
|SWEDEHEART — Improved Outcomes in Patients with Non-ST-Elevation Myocardial Infarction During 20 years are Related to Implementation of Evidence-Based Treatments – Results from the SWEDEHEART Registry 1995-2014||This study evaluated long-term data assessing the changes in outcomes and their relation to implementation of new treatments in patients with non-ST-elevation myocardial infarction (NSTEMI).|
|STIC2IT — Results of the Study of a Tele-Pharmacy Intervention for Chronic Diseases to Improve Treatment Adherence||This randomized trial sought to determine whether this novel, targeted, pharmacist-based intervention improves adherence and disease control.|
|ACS QUIK — Effect of a Quality Improvement Toolkit on Acute Myocardial Infarction in India: The ACS QUIK Cluster Randomized, Stepped Wedge Trial||ACS QUIK sought to evaluate the effect of a locally adapted, evidence-based quality improvement toolkit on process measures and outcomes among patients with acute myocardial infarction in India.|
|ICARE-ACS — National Implementation of a Clinical Guidance Framework for the Emergency Department Assessment of Patients with Possible Acute Coronary Syndromes||This study evaluated the safety and impact of real-life implementation of a national clinical guidance framework for the assessment of possible acute coronary syndromes.|
|DECIDE-LVAD — Effectiveness of a Shared Decision Making Intervention for Patients Offered a Destination Therapy Left Ventricular Assist Device for End-Stage Heart Failure||This study evaluated whether a decision support tool would improve decision quality for left ventricular assist device for destination therapy.|
|STEMI ACCELERATOR-2 — Regional STEMI Systems of Care: Results of the Mission: Lifeline STEMI ACCELERATOR-2 Study||This study evaluated implementation of regional systems of care to provide timely reperfusion for patients with ST-elevation MI.|